Organizations
Conferences
Info & Opinion
March 16, 2010
iGuard expected to draw 60,000 members in a year. Instead, it attracted 750,000. The coming shift in strategy—and genomics.
The world’s largest CRO is seeing a change to its investor mix.
Sponsors are expending much effort to make clinical sites happy. In the last segment of our four-part series, Quintiles discusses its view on the topic.
Has any CRO done more studies using EDC than Quintiles? In picking Phase Forward for most trials, Quintiles says that scalability and preferences at clinical sites helped guide its decision.
Hugo Stephenson is floored by the growth of iGuard, the consumer-oriented online medical monitoring service he started last year with financial support from Quintiles. iGuard turns one this month. When it was launched, Stephenson expected to have perhaps 60,000 people signed…
If all goes as planned, contract research organization (CRO) Quintiles Transnational will have a new mix of owners come January. On Dec. 21, the company announced that one investor is selling its ownership stake, while two others are staying around, and…
Yes, investigator relationship management (IRM) efforts are sweeping through pharmaceutical companies’ headquarters these days, causing all manner of meetings over how to make clinical investigators happy and keep them bringing in quality data. But what of the contract research organization (CRO)?…
We dislike the phrase “tipping point.” It’s been overused to the point of meaninglessness. Malcolm Gladwell’s excellent book isn’t the problem. “Tipping point” should be retired, at least after we borrow its mojo ... just this once. If the story of…
Once again, Phase Forward reported quarterly financial numbers of surprising strength. For its first quarter of 2007, the company logged a double-digit increase of 27 percent in revenue (to $30.1 million). Most of the firm is built around its InForm electronic…